Moberg Pharma AB (publ) (MOB) Q1 2021 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Moberg Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.858 -- 00:00:04.504 Hello and welcome to the Moverd Pharma Q1 report. 00:00:04.504 -- 00:00:08.750 Throughout the call, all participants will be in lithium-aminoid, and afterwards, there 00:00:08.750 -- 00:00:14.499 will be a question or answer session. Just to remind you, this content will be in record. 00:00:14.499 -- 00:00:17.524 Today, I am pleased to present CEO Anna Jung. 00:00:17.524 -- 00:00:20.325 Please go ahead with your meeting. 00:00:20.889 -- 00:00:25.516 Thank you. Hi, my name is Anna Jung, and I'm the CEO of Moverd Pharma. 00:00:25.516 -- 00:00:30.305 I also have our great CEO of Finance, Mark Everidge, on the call today. 00:00:30.305 -- 00:00:35.773 we're happy to present the Q1 report, and you'll find the report on our website, 00:00:35.773 -- 00:00:40.900 and there you'll also have a PowerPoint presentation, and that's the presentation that 00:00:40.900 -- 00:00:45.226 I will be placing this teleconferencing on. 00:00:45.226 -- 00:00:50.013 I'll start on page 3 in that presentation, with an overall. 00:00:50.013 -- 00:00:55.721 We're a Swedish pharmaceutical company that makes products from a variety of known 00:00:55.721 -- 00:01:01.074 substances. which reduces time to market and development risk compared to traditional 00:01:01.074 -- 00:01:02.857 drug development. 00:01:02.857 -- 00:01:07.884 And our lead program is month 15 in Ultima Corpus, and there 00:01:07.884 -- 00:01:14.311 we see a global sales potential of $250 to $500 million annually. 00:01:14.314 -- 00:01:19.321 We recently finalized two large phase 3 trials on more than 800 00:01:19.321 -- 00:01:24.463 patients. and we left Canada on point in these trials and have 00:01:24.463 -- 00:01:29.908 sufficiently satisfied for registration in the EU and we're targeting such...